cardiovascular benefits of glp-1 and drawbacks receptor agonist use. Abbreviations: glp 1 effect on heart

The US Peptide Therapeutics Market has been projected at $52.6 billion in 2025 by Holt Law's market report, reflecting the combined scope of GLP-1 and non-GLP-1 peptide pipeline commercialisation pressure

If you are searching for information related to a product: CT-388 is being investigated as an once-weekly subcutaneous injectable, dual glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide (GLP-1/GIP) receptor agonist for the treatment of obesity and type 2 diabetes (T2D)

Schwiebert C, Irving C, Gillman PK

This designation reflects our ongoing efforts to provide safe, supportive, and high-quality care to every person we serve, while maintaining an environment where everyone can thrive, said Robert Brenner, MD, MMM, FACHE, President and Chief Executive Officer for Valley Health System